This inventor holds 3 USPTO granted patents and 7 published patent applications and 3 EPO patents. Top assignees: Kyowa Hakko Kirin Co., Limited, Kyowa Kirin Co., Ltd., National University Corporation Tokai National Higher Education and Research System. Active years: 2019-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 272 
1 out of 3 
1 out of 130 Years Active: 2019-2026
Title: Fumikazu Shinohara: Innovator in Oligonucleotide Technology
Introduction
Fumikazu Shinohara is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of oligonucleotide technology, holding a total of 3 patents. His work focuses on improving the efficacy of oligonucleotides, which are essential in various biomedical applications.
Latest Patents
Shinohara's latest patents include innovative oligonucleotides designed to enhance affinity for AGO2. One patent describes an oligonucleotide with a specific nucleotide residue configuration that improves knockdown activity against mRNA encoding proteins involved in diseases. Another patent details an oligonucleotide featuring a non-natural nucleotide at the 5' terminal, which also binds to adjacent nucleotide residues through a unique structural arrangement.
Career Highlights
Throughout his career, Fumikazu Shinohara has worked with notable companies such as Kyowa Hakko Kirin Co., Limited and Kyowa Kirin Co., Ltd. His experience in these organizations has allowed him to develop and refine his innovative approaches to oligonucleotide design.
Collaborations
Shinohara has collaborated with esteemed colleagues, including Asana Makino and Junichiro Yamamoto. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.
Conclusion
Fumikazu Shinohara's contributions to oligonucleotide technology highlight his role as a leading inventor in the field. His innovative patents and collaborations reflect his commitment to advancing biomedical research and applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile